Amino acid compound granules (Es Polytamin) have significant effects on nutritional support and metabolic regulation. Discontinuation of medication requires gradual reduction and monitoring of nutritional indicators. The following provides specific explanations from two aspects: evaluation of treatment efficacy and precautions for discontinuing medication.

1. Evaluation of treatment efficacy

(1) Nutritional improvement: Clinical data shows that serum albumin levels increase by an average of 15% -20% after 2-4 weeks of medication, especially for patients with chronic wasting diseases.

(2) Metabolic correction: For patients with hepatic encephalopathy, the ratio of branched chain amino acids to aromatic amino acids can be increased to 3.0 or above, and the effective rate of improving neurological symptoms is about 65%.

(3) Repair promotion: Burn patients experience a 30% reduction in wound healing time after use, which is directly related to an increase in protein synthesis rate.

2. Precautions for discontinuation of medication

(1) Gradual reduction: It is recommended to reduce the dose by 1/4 every 3 days, with a total discontinuation period of no less than 2 weeks, to avoid rebound hypoalbuminemia.

(2) Indicator monitoring: After discontinuing the medication, it is still necessary to test serum prealbumin and transferrin weekly until they stabilize, referring to the liver enzyme monitoring frequency of Liraglutide.

(3) Dietary transition: During the withdrawal period, it is necessary to increase the intake of high protein diet synchronously, and the daily protein intake should be maintained at 1.5-2.0g/kg body weight.

(4) Special population: Patients with renal insufficiency need to extend monitoring to 4 weeks after discontinuing medication, be alert to electrolyte imbalances, and follow the potassium monitoring requirements of eplerenone.